Boostimmune
Boostimmune is a biotech company committed to developing first-in-class therapeutics by targeting innovative and differentiated biological pathways. With a robust pipeline that includes immuno-oncology therapies, antibody-drug conjugates (ADCs), and immune-stimulating antibody conjugates (ISACs), Boostimmune aims to drive true innovation in cancer treatment globally.
Industries
Nr. of Employees
small (1-50)
Patents
Combination of a substance modulating tumor immune microenvironment and immunotherapy for the treatment of cancer
US-12329814-B2
View Details
Combination of a substance modulating tumor immune microenvironment and immunotherapy for the treatment of cancer
US-12329814-B2
View DetailsProducts
BIO101 (anti-TCTP antibody therapeutic candidate)
An antibody candidate that binds extracellular TCTP to reduce tumor-infiltrating myeloid-derived suppressor cells (MDSCs), activate anti-tumor immune cells and produce anti-tumor responses in preclinical models.
BIO103 (ADC candidate with TOP1 inhibitor payload)
An antibody-drug conjugate targeting an oncofetal antigen and conjugated to a TOP1 inhibitor payload, with reported strong efficacy in xenograft models and non-GLP safety data in non-human primates.
BIO104 (ADC candidate targeting Wnt/β-catenin–associated membrane protein)
An ADC designed to target a membrane protein induced by Wnt/β-catenin signaling that undergoes rapid internalization, demonstrating efficacy and safety in xenograft models with Wnt pathway mutations.
BIO105 (ISAC program)
An immune-stimulating antibody conjugate program listed in the pipeline (ISAC platform), intended to stimulate immune responses in the tumor microenvironment.
BIO101 (anti-TCTP antibody therapeutic candidate)
An antibody candidate that binds extracellular TCTP to reduce tumor-infiltrating myeloid-derived suppressor cells (MDSCs), activate anti-tumor immune cells and produce anti-tumor responses in preclinical models.
BIO103 (ADC candidate with TOP1 inhibitor payload)
An antibody-drug conjugate targeting an oncofetal antigen and conjugated to a TOP1 inhibitor payload, with reported strong efficacy in xenograft models and non-GLP safety data in non-human primates.
BIO104 (ADC candidate targeting Wnt/β-catenin–associated membrane protein)
An ADC designed to target a membrane protein induced by Wnt/β-catenin signaling that undergoes rapid internalization, demonstrating efficacy and safety in xenograft models with Wnt pathway mutations.
BIO105 (ISAC program)
An immune-stimulating antibody conjugate program listed in the pipeline (ISAC platform), intended to stimulate immune responses in the tumor microenvironment.
Services
Joint research and translational collaborations with hospitals and academic centers to advance target validation, biomarker studies and preclinical development.
Execution of in vivo efficacy studies, early toxicology assessments and candidate optimization to support IND-enabling programs.
Joint research and translational collaborations with hospitals and academic centers to advance target validation, biomarker studies and preclinical development.
Execution of in vivo efficacy studies, early toxicology assessments and candidate optimization to support IND-enabling programs.
Expertise Areas
- Immuno-oncology drug discovery
- Antibody-drug conjugate (ADC) development
- Target discovery and validation for tumor-specific antigens
- Preclinical in vivo pharmacology (syngeneic, xenograft, PDX)
Key Technologies
- Antibody engineering
- Antibody-drug conjugates (ADC)
- Immune-stimulating antibody conjugates (ISAC)
- In vivo xenograft models